Bajaj Healthcare (BHL) has launched API and Formulation of ‘DGJAJ’ (2-Deoxy-D-Glucose), an antiviral drug used for treating COVID patients, in collaboration with Defence Research and Development Organisation (DRDO). BHL had received a license agreement from DRDO on July 7, 2021, to manufacture and market 2-Deoxy-D-Glucose (2-DG). The production of ‘DGJAJ’ commenced from September 4, 2021 onwards.
2-Deoxy-D-Glucose (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virusinfected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1800.30 |
Dr. Reddys Lab | 1275.05 |
Cipla | 1472.05 |
Lupin | 2098.70 |
Zydus Lifesciences | 979.10 |
View more.. |